Needham & Company LLC Reaffirms “Buy” Rating for Bicycle Therapeutics (NASDAQ:BCYC)
Needham & Company LLC reiterated their buy rating on shares of Bicycle Therapeutics (NASDAQ:BCYC – Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $30.00 price objective on the stock. BCYC has been the subject of several other reports. Stephens reissued an “equal weight” rating and […]
Needham & Company LLC reiterated their buy rating on shares of Bicycle Therapeutics (NASDAQ:BCYC – Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $30.00 price objective on the stock. BCYC has been the subject of several other reports. Stephens reissued an “equal weight” rating and […]
